CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies

Most hematological malignancies are characterized by overexpression of certain cancer promoting genes, such as MYC, MCL1 and cyclin D1. Preclinical studies in animal models have shown that CDK9 inhibitors supress the transcription of these anti-apoptotic and pro-survival proteins, and suggest their...

Descripción completa

Detalles Bibliográficos
Autores principales: Morillo, Daniel, Vega, Gala, Moreno, Victor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Research Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408673/
https://www.ncbi.nlm.nih.gov/pubmed/37552223
http://dx.doi.org/10.18632/oncotarget.28473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408673/
https://www.ncbi.nlm.nih.gov/pubmed/37552223
http://dx.doi.org/10.18632/oncotarget.28473

Ejemplares similares